Brief: Mira Pharmaceuticals Advances Preclinical Trials Towards An Ind Submission This Year For Ketamir-2, A Differentiated Oral Ketamine Analog
20/05/2024 13:29
Mira Pharmaceuticals Inc MIRA.O :
* MIRA PHARMACEUTICALS ADVANCES PRECLINICAL TRIALS TOWARDS
AN IND
SUBMISSION THIS YEAR FOR KETAMIR-2, A DIFFERENTIATED ORAL
KETAMINE ANALOG
* MIRA PHARMACEUTICALS-ANTICIPATES POSITIVE RESULTS FROM
THESE
PRECLINICAL STUDIES WILL ENABLE SUBMISSION OF IND APPLICATION TO
FDA BY END OF THIS YEAR
Source text for Eikon: ID:nPnc5cwCJa
Further company coverage: MIRA.O
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing